December 12, 2013 | BrainStorm Cell Therapeutics, a developer of adult stem cell technologies for neurodegenerative diseases, has announced that it was awarded an $800,000 non-dilutive grant from Israel’s Office of the Chief Scientist (OCS) for the year 2014. The grant is intended to support BrainStorm’s clinical and product development for its stem cell therapy candidate NurOwn.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments